Log in to search using one of your social media accounts:

 

Ixazomib (Ninlaro) combination rejected for multiple myeloma in second draft guidance

The National Institute for Health and Care Excellence  (NICE) has again rejected ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone (IRd) for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more previous therapies.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research

Related Links:

We report an extremely rare case of multiple myeloma (MM) [IgD-lambda (λ) type, stage III B] with MPE as initial presentation and complicated with massive pericardial effusions during the progression of the disease. Cytological identification of malignant plasma cells in pleural effusion is the most direct method to diagnose MPE. What we learn from this case is that cell block can increase the sensitivity of detecting malignancies compared with conventional smear. Doctors should make best use of pleural effusion before further invasive procedure. PMID: 28932581 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Conclusion The use of RT in NLPHL is less likely among those with advanced-stage and B-symptoms. However, we found RT to be associated with prolonged OS in all stages of NLPHL, including those with B-symptoms. Teaser We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 23 September 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): José L. Ortega, Fernando Cabanillas, Noridza Rivera, Maribel Tirado-Gomez, Deana Hallman, Wandaly I. Pardo, Margarita Bruno
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion A single-institutional retrospective analysis found no significant differences in outcomes using GCLAC or CLAG for rrAML patients, though formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was higher than CLAG which should be considered when evaluating salvage chemotherapy options.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We present a review of the literature and describe the presentation, differential diagnosis, treatment options and outcomes of CNS EMZBL.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Marginal zone lymphomas (MZL) represent a group of indolent lymphomas that originates from the marginal zone of lymphoid tissue. [1-3] The World Health Organization classifies these indolent lymphomas into three distinct types based on their site of origin: extranodal mucosa-associated lymphoid tissue (MALT) MZL, nodal MZL (NMZL) and the splenic MZL (SMZL). Even though these entities share common features, they also display clinical, molecular and biological heterogeneity depending on the organ where they originate from.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Network, S J Russell &A K Stewart
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
In this weeks video, Dr. Brian GM Durie explains why myeloma protein spikes after an ASCT are most likely not cause for alarm.BOTTOM LINE: If your myeloma protein spikes after ASCT, monitor c... Author: InternationalMyelomaFoundation Added: 09/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Join the IMFs Medical Editor Debbie Birns and Dr. Rafat Abonour for a Living Well with Myeloma webinar on Making Sense of Tests and Results. Debbie will outline the various tests that are used to d... Author: InternationalMyelomaFoundation Added: 09/21/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Dexamethasone | Drugs & Pharmacology | Myeloma | National Institute for Health and Clinical Excelle | Revlimid